ADELAIDE, Australia / RankWire.AI / – Researchers in Australia, affiliated with Adelaide University and the Olivia Newton-John Cancer Research Institute, have discovered a new molecular switch that promotes the metastasis of aggressive tumors. Their findings, published in EMBO Molecular Medicine, highlight a promising method to combat triple-negative breast cancer by reactivating a vital regulatory molecule called miR-342. This breakthrough paves the way for strategies to prevent secondary cancers in vital organs such as the lungs and bones.
While triple-negative breast cancer represents 10% to 15% of the approximately 21,000 breast cancer diagnoses each year in Australia, it accounts for a disproportionately high number of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, making traditional hormone-targeted therapies ineffective. The researchers demonstrated that when miR-342 levels decline, the E2F pathway, which fuels cancer progression, becomes overactive, enabling dormant cancer cells to disseminate and generate dangerous secondary tumors throughout the body.
Potential for Patient Stratification via Biomarker Testing
In experimental models, scientists showed that increasing miR-342 levels significantly limited the spread of cancer to distant organs. They also found that palbociclib, an approved CDK4/6 inhibitor used for hormone receptor-positive breast cancers, effectively suppressed metastatic tumor growth in models with low miR-342 levels. These results indicate that testing for miR-342 could help clinicians repurpose existing drugs for high-risk patients.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, confirmed that preventing metastasis remains the biggest hurdle in treating aggressive breast cancers. Gregory emphasized that because palbociclib targets the hyperactive E2F pathway, administering the drug after cancer cell spread can prevent the growth of microscopic deposits. Instead of just shrinking primary tumors, this therapeutic approach aims to stop tiny secondary cancers from evolving into life-threatening conditions.
miR-342 Serves as a Key Regulator for Cancer-Related Genes
The research team pointed out that triple-negative breast cancer exhibits significant biological diversity, which has traditionally impeded the development of universal targeted therapies. By identifying a specific vulnerability common to a distinct patient subgroup, the study offers a pathway toward personalized treatment options. As Australian scientists continue to explore this promising approach, efforts are underway to validate the findings using patient-derived models before moving into clinical trials.
The findings have been welcomed by medical oncologists and cancer research organizations throughout Australia, who stressed the critical need for expanded treatment options when standard therapies fall short. The research team aims to work with international clinical networks to speed up biomarker screening processes. Confirming the utility of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor treatments early in the disease course.